Clovis Oncology Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 70 Posts
1 2 3 ... 5
5 Drug/Biotech Stocks Likely To Beat Q4 Earnings Estimates
Article By: Zacks Investment Research Monday, February 17, 2020 10:34 AM EDT
The Medical sector has witnessed a fairly good run in this earnings cycle so far.
In this article: IMMU, CLVS, PRGO, VTVT, ETON Also: JNJ, GILD
Read
Clovis Oncology (CLVS) Buy Level Approaching
Article By: Gareth Soloway Thursday, December 5, 2019 2:04 PM EDT
Shares of Clovis Oncology, Inc. (CLVS​) continue to retrace the massive up-move seen recently.
In this article: CLVS
Read
Stock Charts To Watch - Monday, December 2
Video By: Harry Boxer Monday, December 2, 2019 9:51 PM EDT
Clovis Oncology, Inc. was up 1.50, or 10%, to 16.43, with a high of 17.37, on 40 million shares on Monday. This stock has been a monster.
In this video: X, CLVS, BYND, PBYI, WWE, TWLO
Watch
Stock Charts To Watch - Monday, November 18
Video By: Harry Boxer Monday, November 18, 2019 11:00 AM EDT
Advanced Micro Devices, Inc. hit one penny off my 40-dollar target on Monday.
In this video: AMD, OESX, INMD, SEAC, CLVS, COLL, CRSP, MAXR
Watch
Tesaro Jumps After Report Of Sale Exploration, Peer Clovis Follows
Article By: The Fly Friday, November 16, 2018 7:40 PM EDT
Shares of Tesaro (TSRO) jumped in late day trading after Bloomberg said the company is working with advisers to explore a possible sale after receiving takeover interest.
In this article: CLVS, TSRO
Read
Clovis Jumps As Analysts Get More Bullish Following EU Advisory News
Article By: The Fly Thursday, February 22, 2018 11:47 AM EDT
Shares of Clovis are on the rise after Evercore ISI analyst Steven Breazzano upgraded the stock to Outperform.
In this article: CLVS Also: TSRO
Read
Clovis Oncology Submits Supplemental New Drug Application For Rucaparib
Article By: Business Wire Monday, October 9, 2017 9:14 PM EDT
CLVS announced today that the company has submitted a supplemental New Drug Application (sNDA) to the FDA for rucaparib as maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer .
In this article: CLVS
Read
XBI Breaks Through On A Strong Week For Biotech
Article By: Rod Raynovich Friday, September 29, 2017 7:25 PM EDT
The XBI is up 3.17% this week, 46% YTD, compared to only 1.1% WTD for the IBB. The breakthrough gains for the XBI can be attributed to strong performance of top ten holdings that are primarily mid-caps and M&A prospects.
In this article: BMY, ALNY, BMRN, IBB, AMGN, CELG, CLVS, XBI, JUNO, PBYI, SRPT, BLUE, PTCT, ABBV, FMI
Read
Good Day Today: XBI Breaks Through To YTD Highs
Article By: Rod Raynovich Monday, June 19, 2017 9:31 PM EDT
Tech stocks rebounded today and biotech stocks soared and maintained the market lead in 2017 performance.
In this article: BMY, ALNY, BMRN, INCY, QQQ, AMGN, CLVS, GILD, XBI, XLV, ICPT, BLUE, RDUS, IBB
Read
ASCO Update #2: Stock Performance Data As Of 6/8/17
Article By: Rod Raynovich Friday, June 9, 2017 6:24 PM EDT
Biotechnology stocks are driven by clinical and deal news so here are some trends to consider.
In this article: CLVS, XBI, PUMA, KITE, BLUE, LOXO
Read
Biotech Fades After ASCO Abstract Rally
Article By: Rod Raynovich Friday, May 26, 2017 6:29 PM EDT
Biotechs faded today now that the rush of oncology drug news cooled down. Today was dominated by the “red screen” with profit taking mainly in smaller caps and momentum driven oncology stocks.
In this article: MRK, ALNY, ALXN, BMRN, INCY, CELG, CLVS, VRTX, ZIOP, JUNO, PBYI, EPZM, GLYC, KITE, TSRO
Read
Best Stock Charts - Tuesday, May 23
Video By: Robert Desmond Tuesday, May 23, 2017 11:47 PM EDT
I am concerned about the markets and their ability to break out to new highs. Caution flag is on the track because if the rally fails you will want to buy risk off assets such as health care and commodities.
In this video: DDD, LSI, IRBT, AAPL, CLVS, GDXJ, IWM, USLV, UUP, FB, TWTR, FEYE, LABU, PI
Watch
ASCO Abstracts Week: Biotech Trends And Hot Stocks
Article By: Rod Raynovich Monday, May 22, 2017 10:58 PM EDT
Today Amgen was down over 2 % on news that its osteoporosis treatment Evenity is unlikely to win FDA approval this year because of a safety risk. Radius Health was up over 6% to $37.30 as their rival drug Tymlos was approved in April.
In this article: MRK, ALNY, IBB, INCY, REGN, AMGN, CLVS, VRTX, FBT, XBI, PUMA, JUNO, EPZM, GLYC, KITE, BLUE, RDUS
Read
Rayno BioBeat 2017 #2: Biotech Breakthrough Rally
Article By: Rod Raynovich Monday, February 27, 2017 11:09 PM EDT
Biotech stocks got a second wind today and the 2017 rally broke through recent tops that have been strong resistance.
In this article: RHHBY, ALNY, ARRY, BMRN, IBB, REGN, SGEN, BIIB, CLVS, VRTX, XBI, ICPT, BLUE, FMI, TSRO
Read
Rayno Biobeat 2017 #1: Biotech Rally Driven By M&A
Article By: Rod Raynovich Friday, February 10, 2017 4:00 PM EDT
Biogen looking good in here at $275+, up 4.2% over five days, down 2.7% YTD. IBB and XBI​ slight gains.
In this article: ACOR, ALNY, ARRY, IBB, REGN, SGEN, AMGN, BIIB, CLVS, HOLX, XBI, AGIO, BLUE, FMI, TSRO
Read
Conatus Soars On Novartis Deal, Early FDA Nod For Clovis Drug
Article By: Arpita Dutt Wednesday, December 21, 2016 10:55 AM EDT
Conatus is ending the year on a high note with the company signing a lucrative deal with Swiss pharma giant, Novartis. Investors applauded the deal sending the company’s shares soaring 141.3%.
In this article: ALIOF, ALXN, BIIB, CLVS, GILD, CNAT, TSRO
Read
1 to 16 of 70 Posts
1 2 3 ... 5